1. A colorimetric dry-reagent test strip for direct detection of the presence of hydrogen peroxide in strongly acidic solutions without the necessity of a neutralization step, consisting essentially of a chromogen responsive to hydrogen peroxide, an enzyme peroxidase catalyst and at least one complexing agent at a concentration that effectively protects an active site of the catalyst for an amount of time sufficient to allow for the catalytic oxidation of the chromogen when contacted with hydrogen peroxide-containing solutions having a pH in the range of 0 to 1, wherein the components are in a dry form on a carrier.
b) heating the first solution or the second solution in the presence of a solid acidic zeolite catalyst containing aluminum as the only metal (Zeolite-Al).
measuring the rate at which the pH of the newly mixed solution equilibrates under the influence of the enzyme to determine carbonic anhydrase activity.
and a biosensor for determining the level of generated H2O2.
1. A process for decontaminating surfaces contaminated with at least one toxic agent, comprising applying onto said contaminated surfaces a decontamination composition comprising an aqueous or non-aqueous carrier liquid and at least two types of Zr(OH)4 including a first type Zr(OH)4 and a second type Zr(OH)4, wherein said first type Zr(OH)4 has an average particle size of up to 100 nm and said second type Zr(OH)4 has an average particle size of at least 10 ?m, and wherein said decontamination composition has a weight ratio of said first type Zr(OH)4 to said second type Zr(OH)4 in the range of about 5:1 to 2:1.
d) preparing a gene fragment library by ligating the nucleic acid fragments to nucleic acid adaptors.
(g) determining a value indicative for the presence and/or amount of reporter compound captured on the binding member.
marker TY38 corresponding to the 21st nucleotide of SEQ ID NO: 22to identify a root-knot nematode resistance locus on chromosome 4 and select a root-knot nematode resistant tomato plant comprising the marker, andcrossing the root-knot nematode resistant tomato plant comprising the root-knot nematode resistance locus on chromosome 4 with a cultivated tomato plant to produce a progeny plant, wherein the progeny plant has the root-knot nematode resistance locus on chromosome 4.
the pH and/or conductivity of the second elution buffer are/is greater than that of the first elution buffer.
wherein the first onium salt acid generator and the second onium salt acid generator are each not bound to a polymer.
1. A Solanum lycopersicum tomato plant designated variety 72-759 RZ, representative seed of which having been deposited under NCIMB Accession No. 42682.
the VWF comprises a full-length VWF polypeptide.
4. A positive resist composition comprising the polymer according to claim 1 and a solvent.
1. A seed of hybrid tomato designated 58811, wherein a representative sample of seed of said hybrid has been deposited under NCIMB No. 42749.
1. A tomato seed of tomato hybrid SV6133TM, a sample of seed of said hybrid SV6133TM having been deposited under ATCC Accession Number PTA-122352.
1. Tomato seed designated as H1538, representative sample of seed having been deposited under ATCC Accession Number PTA-124277.
1. An isolated peptide comprising an amino acid sequence being at least 80% homologous to the sequence as set forth in SEQ ID NO: 1(PERYQNLSPV), the isolated peptide comprising a nuclear targeting activity, the peptide being no longer than 20 amino acids.
(e) repeating steps (a) through (d) to identify a sequence of the primed template nucleic acid.
using the healing template to inhibit the one or more subsequent attacks.
1. A seed of cotton variety designated PX2048-04WRF, or a regenerable part thereof, representative seed of the variety having been deposited under ATCC Accession No. PTA-122544.
1. A seed of cotton variety designated PHY764WRF, or a regenerable part thereof, representative seed of the variety having been deposited under ATCC Accession No. PTA-122543.
1. A method of inhibiting a calcium ion channel, the method comprising contacting the calcium ion channel with a conotoxin peptide ?-CPTx-btl02, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 1, and wherein the peptide contains three pairs of disulfide bonds.
(f) producing a representation of the nucleotide sequence for the target nucleic acid polymer based on the nucleotide sequences from the fragments and the determined relative physical distances between the locations on the solid support surface, wherein the relative physical distances are indicative of distances between the sequence regions along a given strand of the target nucleic acid polymer.
1. A plant or a seed of soybean variety 5PNJE71, representative seed of the variety having been deposited under ATCC Accession Number PTA-125150.
and which has an elongation of up to at most 1% under a tensile force of at least 3 N per 25 mm width in accordance with DIN EN ISO 527-3 and has no embossed structure on its surface layers.
h. (i) identifying the test compound as a candidate compound for slowing down the progression of or treating pre-MCI or MCI if the ratio of the levels of the miRNAs calculated in step (f) is lower than the ratio of the levels of the miRNAs calculated in step (c); (ii) identifying the test compound as not a candidate compound for slowing down the progression of or treating pre-MCI or MCI if the ratio of the levels of the miRNAs calculated in step (f) is not lower than the ratio of the levels of the miRNAs calculated in step (c).
1. A plant or a seed of soybean variety 5PBDN11, representative seed of the variety having been deposited under ATCC Accession Number PTA-125151.
wherein A is a transmembrane protein domain of synaptobrevin targeted to an intracellular vesicle membrane and is not cleavable by a Botulinum neurotoxin protease, B is a first fluorescent protein, C is a first linking domain comprising a Botulinum neurotoxin protease recognition sequence and a Botulinum neurotoxin protease cleavage sequence, C? is a second linking domain comprising an analog of C that includes the Botulinum neurotoxin protease recognition sequence but not the Botulinum neurotoxin protease cleavage sequence, and D is a second fluorescent protein selected to form a Förster resonance energy transfer (FRET) pair with the first fluorescent protein, wherein said transmembrane domain, said peptide spacer, and said BoNT protease recognition and cleavage sequence are selected to support FRET between said first fluorescent protein and said second fluorescent protein when said first hybrid protein and said second hybrid protein are collocated with a vesicle.
wherein said method does not comprise measuring more than 29 biomarkers.
1. A composition of matter, comprising:lyotropic semiconducting polymers each having a donor-acceptor copolymer backbone and a side chain attached to the backbone, wherein the donor-acceptor copolymer backbone comprises fused aromatic rings.
1. A corn plant comprising at least a first set of the chromosomes of corn line SYY6S-14NN18, a sample of seed of said line having been deposited under ATCC Accession Number PTA-124217.
1. A method of making a synthetic or recombinant polypeptide capable of forming at least a first crystal-forming domain block and at least a first amorphous domain block, the method comprising selecting an amino acid sequence that is capable of forming the first crystal domain block, wherein the crystal domain block is from about 2 nm to about 5 nm long and comprises from 10 to 30 amino acids, and selecting an amino acid sequence that is capable of forming a first amorphous domain block, wherein the first amorphous domain block is about 3 nm long and comprises about 15 amino acids, and forming the synthetic or recombinant polypeptide by incorporating [i] the amino acid sequence comprising AA[XXXXXX]HH (SEQ ID NO: 313), wherein the XXXXXX comprises histidine, threonine, valine, alanine, serine, or a combination thereof that is capable of forming the first crystal-forming domain block and [ii] the amino acid sequence comprising a glycine rich sequence according to Table 6 that is capable of forming the first amorphous domain block into the synthetic or recombinant polypeptide.
wherein said cell-free test sample is a supernatant isolated from the whole urine sample, wherein the whole urine sample has been processed to eradicate contamination with any urothelial or microbiological cell material.
1. A seed of the hybrid corn variety 15711553, produced by crossing a first plant of variety 3EESL0003 with a second plant of variety XHE06, wherein representative seed of said varieties 3EESL0003 and XHE06 have been deposited under ATCC Accession numbers PTA-123410 and PTA-12583, respectively.
wherein the outer surface hardness of the outer core layer is greater than the outer surface hardness of the inner core layer.
5) the monoclonal antibody or an antigen binding fragment selected from a humanized antibody, a chimeric antibody or a single chain antibody made from any of the monoclonal antibodies as described in 1-4 above.
b) detecting binding between the PKN1 gene fusion and the oligonucleotide.
1. Seed of corn inbred line designated 3EESL0003, or a part thereof, representative seed of the line having been deposited under ATCC Accession No. PTA-123410.
1. A polypeptide comprising at least one amino acid substitution at a position corresponding to T354 of the amino acid sequence of SEQ ID NO: 1, wherein the polypeptide has at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 1, and wherein the polypeptide has an in vitro and/or in vivo pentose transport function.
(d2) the presence of cells stained with the label generating the first reporter signal and the absence of cells stained with the label generating the second reporter signal.
1. A plant of soybean variety 01068084, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-124739.
1. An analogue of Stichodactyla helianthus toxin ShK comprising an ShK toxin polypeptide and an N-terminal extension selected from the group consisting ESSS (SEQ ID NO: 1), EWSS (SEQ ID NO: 2), EESS (SEQ ID NO: 5), EWST (SEQ ID NO: 6), EWTT (SEQ ID NO: 7), EWTS (SEQ ID NO: 8) and SEWSS (SEQ ID NO: 9).
(b) producing a quantitative profile of clonotyes identified in step (a)(2) that correlate with the disease in the subject, wherein the profile comprises sequences and levels of said clonotypes.
1. A plant of soybean variety 01064265, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-124747.
1. A PYY compound comprising tryptophan at the position corresponding to position 30 of hPYY(1-36) (SEQ ID NO:1), a maximum of 8 amino acid modifications as compared to hPYY(3-36), wherein the PYY compound comprises N(alpha)-methyl-L-arginine at a position corresponding to position 35 of hPYY(1-36) (SEQ ID NO:1), and wherein the positions corresponding to positions 1-2 or 1-3 of hPYY(1-36) (SEQ ID NO:1) are absent, or a pharmaceutically acceptable salt thereof.
a treatment system operable to provide a treatment to the user based on characterizing the user with the characterization model in relation to the mouth-associated condition.
1. A plant of soybean variety 01064571, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-124755.
1. An aqueous polymer emulsion, comprising a core-shell type polymer particle dispersed in water,wherein the core-shell type polymer particle comprises a shell part composed of an amphoteric ion polymer (A) and a core part composed of a hydrophobic polymer (B).
c) a flexible linker region, wherein the flexible linker region is flanked on one side by a region encoding a C-terminal portion of a circularly permutated fluorescent protein and on the other side by a region encoding the N-terminal portion of the circularly permutated fluorescent protein, and wherein said C-terminal portion of said circularly permutated fluorescent protein and said N-terminal portion of said circularly permutated fluorescent protein form a functional fluorescent protein when said histone-modification-specific binding domain binds to said histone polypeptide substrate.
e) producing a progeny plant from the cross of d), wherein said progeny plant comprises the haplotype detected in b), thereby producing a soybean plant having ASR resistance.
1. A plant, plant part, seed, or plant cell of wheat variety W070474I1, representative seed of said variety having been deposited under ATCC accession number PTA-123444.
1. A pharmaceutical composition comprising a capsule containing crystals of spray-dried oxalate decarboxylase comprising the amino acid sequence of SEQ ID NO:1 where the thiol moiety at Cys383 is protected by a reaction with a thiol protecting group, wherein the crystals have a Hausner ratio of about 1.00 to about 1.59.
1. A plant of soybean variety 01064594, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-124891.
1. A recombinant human cytolytic fusion protein (hCFP) suitable to induce apoptosis in human target cells, comprising a target cell-specific binding component and a human effector domain, wherein the binding component comprises an antibody or an antibody fragment with an antigen-binding site for binding to the cellular surface receptor CD64, and the effector domain comprises a variant or a functional fragment of wild type human angiogenin (Ang) as shown in SEQ ID NO: 1, wherein the variant of the wild type human angiogenin as shown in SEQ ID NO: 1 contains at least substitutions at positions that correspond structurally or by amino acid sequence homology to positions 85, 86 and 117, and wherein the substitutions are G85R, G86R and Q117G.
the silica particle has a volume resistivity of at least 1.0×1014 ?·cm and no greater than 1.0×1016 ?·cm.
1. A plant of soybean cultivar S170008, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-124445.
1. A fusion polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 3-19.
wherein a number density of a void having a circle equivalent diameter of 0.02 ?m to 3.0 ?m is 2000 mm?2 or less in the metallographic structure.
wherein when an average particle diameter of the brilliant pigments included in the developer particles is expressed as D (?m), a number proportion of the developer particles having particle diameters in a range from 4 ?m to 1.2×D ?m in whole developer particles is less than or equal to 4%.
1. A plant of soybean cultivar S170003, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-11124446.
1. A dentifrice comprising a zinc-amino acid-halide complex, wherein the amino acid is lysine, and complex is a zinc lysine chloride complex having the chemical structure [Zn(C6H14N2O2)2Cl]+Cl?, either in solution of the cation [Zn(C6H14N2O2)2Cl]+ and the chloride anion, or in solid salt form, optionally in mono- or dihydrate form.
1. A conjugate comprising interleukin-22 (IL22) and an antibody molecule, wherein the antibody molecule comprises an antigen-binding site which binds the Extra Domain-A (ED-A) of fibronectin and comprises the complementarity determining regions (CDRs) of antibody F8 set forth in SEQ ID NOs 1-6, and wherein the IL22 comprises the sequence set forth in SEQ ID NO: 11.
forming the blank at the forming temperature below the Ac1 transformation temperature into the component while still maintaining the partly martensitic transformation microstructure and the residual austenite microstructure in the component.
1. A plant of soybean cultivar S170024, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-124464.
wherein the fusion protein exhibits an improved pharmacokinetic profile when administered to a subject compared with the TP by itself.
all powder constituents together being 100 weight percent.
1. A carrier which is a core material composed of a magnetic component and a non-magnetic component coated with a resin, characterized in thatthe carrier has water content of 200 ppm or less and cyclic siloxane content of 100 ppb or less.
1. A plant of soybean cultivar S170022, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-124448.
1. A topical, reductive cosmetic composition, comprising up to 15% by weight of hydrolyzed keratin and micrometer-sized Sulphur, and a remainder of the composition comprising water, compatibilizers, surfactants, thickeners, preservatives and/or flavoring agents.
and wherein opening of the chloride channel receptor is induced by pH.
1. A plant of soybean cultivar S170017, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-124447.
wherein the first and second targeting domains bind to different sites on HIV Env, and wherein the multispecific chimeric antigen receptor protein binds to HIV Env.
1. A seed of lettuce line SVLN7347, a sample of seed of said line having been deposited under ATCC Accession Number PTA-123429.
1. A method for reducing formation of fibrosis in at least one nasolacrimal duct of a patient that may occur upon the patient receiving radioactive iodine, the method comprising administering to the patient a therapeutically effective amount of perchlorate anion, wherein the administering is topically administering perchlorate anion to at least one eye of the patient, or instilling the perchlorate anion directly into the at least one nasolacrimal duct or at least one lacrimal sac of the patient.
wherein the sample, after (b) comprises the target antibody and a reduced amount of the aggregates, wherein the sample is derived from a cell culture or cell culture supernatant, and the target antibody is a recombinant antibody.
1. A spinach seed comprising at least a first set of the chromosomes of spinach line SSBS012-1181F, a sample of seed of said line having been deposited under ATCC Accession Number PTA-124049.
the amount of the botanical powder is distributed in a biopolymer-sugar based matrix.
1. An anti-VEGF antibody or an antigen-binding fragment thereof comprisinga CDR-H1 comprising the amino acid sequence of SEQ ID NO: 110, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 121, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 129, a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 137, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 145, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 151.
1. A seed of canola designated CL3701975H, wherein a representative sample of seed of said cultivar was deposited under ATCC Accession No. PTA-123165.
1. A nucleic acid molecule encoding a humanized antibody that binds to at least two CCR3-binding chemokines wherein said nucleic acid molecule comprises the sequence denoted by SEQ ID NO: 1 and SEQ ID NO: 2.
1. A seed, plant, plant part, or plant cell of inbred maize variety PH42YV, representative seed of the variety having been deposited under ATCC accession number PTA-124767.
1. A method of delivery of messenger RNA (mRNA) to a non-lung cell or tissue comprising administering to the lung by nebulization a composition comprising mRNA encoding a protein and a lipid carrier vehicle comprising one or more PEG-modified lipids, wherein the administering to the lung results in the delivery of the mRNA to a non-lung cell or tissue, and wherein the protein encoded by the mRNA is detectable in the non-lung cell or tissue for at least 6 hours following the administration to the lung.
wherein the rat or mouse further comprises a population of mature IgMintIgDhi B cells in its spleen, each B cell comprising a distinct rearranged human heavy chain variable region gene sequence derived from the restricted immunoglobulin heavy chain locus.
where, symbols of elements in Formulae (1) and (2) are substituted by corresponding contents (by mass %) of the elements.
1. A seed, plant, plant part, or plant cell of inbred maize variety PH2FNV, representative seed of the variety having been deposited under ATCC accession number PTA-125259.
wherein 80% -90% of the total weight of the water-soluble active agent is found in the lower 33% of the total volume of the hydrophilic polymer foam, which is the volume of the foam closest to the impermeable nonporous support at the end of step d).
(f) a monoclonal antibody having (i) a heavy chain comprising CDR 1, 2 and 3 (HCDR1, HCDR2, HCDR3) comprising a sequence of SEQ ID NO: 48 (HCDR1), SEQ ID NO: 51 (HCDR2) and SEQ ID NO: 53 (HCDR3), respectively, and (ii) a light chain comprising CDR 1, 2 and 3 (LCDR1, LCDR2, LCDR3) comprising a sequence of SEQ ID NO: 54, 55 and 56, respectively.
1. A process for surface hardening a workpiece made from an iron, nickel and/or chromium based alloy by gas carburization in which an unsaturated hydrocarbon is contacted with the workpiece inside a carburization reactor under a pressure of about 3.5 to 100 torr and at an elevated carburization temperature to cause carbon to diffuse into the workpiece surfaces thereby forming a hardened primary surface layer which is essentially free of carbide precipitates as well as a thermal oxide film, the process further comprising increasing the rate at which carburization occurs by feeding a carbon-free, halogen-containing activating compound to the carburization reactor simultaneously with feeding the unsaturated hydrocarbon to the carburization reactor, wherein the unsaturated hydrocarbon is acetylene, the concentration of the of the unsaturated hydrocarbon inside the carburization reactor is about 8 to 35 vol. % and the concentration of the carbon-free, halogen-containing activating compound inside the carburization reactor is about 0.5 to 3 vol. %.
1. A seed of soybean variety 38G14B4189, wherein a representative sample of the seed having been deposited under ATCC Accession No. PTA-125136.
wherein said concentrate is substantially free of a base component that is suitably used in dialysis, and the second component comprises MgCl2, CaCl2 and KCl.
1. A fusion polypeptide capable of binding simultaneously to VEGF-C and VEGF-D, comprising a VEGFR2 extracellular domain, a VEGFR3 extracellular domain, and the Fc region of an immunoglobulin, wherein the VEGFR2 extracellular domain comprises Ig-like domain 2, and the VEGFR3 extracellular domain comprises Ig-like domain 2.
1. A plant or a seed of soybean variety 5PESH71, representative seed of the variety having been deposited under ATCC Accession Number PTA-125283.
1. A microsphere comprising a core material, wherein the microsphere has a circularity greater than 0.95 and an aspect ratio of shortest diameter to longest diameter that is greater than 0.95, wherein the microsphere has a skeletal density from about 1.4595 g/cc to about 1.4651 g/cc, and wherein the microsphere has a moisture gain of less than 1.0% at 90% relative humidity.
1. A plant or a seed of soybean variety 5PQNE01, representative seed of the variety having been deposited under ATCC Accession Number PTA-125284.
administering to said male subject a therapeutically effective amount of a composition comprising Denosumab or an antigen binding domain thereof, or osteoprotegerin (OPG).
1. A plant of corn variety CV754236, wherein representative seeds of corn variety CV754236 have been deposited under ATCC Accession No. PTA-124508.
1. An isolated anti-CD20 single domain antibody comprising the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 5, or SEQ ID NO: 6.
1. A plant of soybean variety 01068058, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-124886.
1. A method of treating a disorder associated with a mutation or loss of function in a fukutin related protein (FKRP) gene in a subject, comprising administering a therapeutically effective amount of a ribitol to a subject in need thereof daily for at least 30 days, thereby treating the disorder associated with a mutation or loss of function in a fukutin related protein (FKRP) gene in a subject, wherein the disorder associated with a mutation or loss of function in the FKRP gene is selected from the group consisting of limb-girdle muscular dystrophy (LGMD), Walker-Warburg syndrome (WWS), muscle-eye-brain disease (MEB), congenital muscular dystrophy (CMD), and any combination thereof.
k) a VH sequence of SEQ ID NO: 26 and a VL sequence of SEQ ID NO: 25.
1. A plant of soybean variety 01064667, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-124966.
wherein the one or more amino acids includes L-Lysine HCL and L-Glutamine.
a ligand which binds specifically to an effector cell.
1. A seed, plant, plant part, or plant cell of inbred maize variety PH42KS, representative seed of the variety having been deposited under ATCC accession number PTA-124768.
(e) compressing the tablet mixture into a tablet.
1. An antibody or an antigen-binding fragment thereof, binding to carbonic anhydrase, wherein the antibody or antigen-binding fragment thereof comprises a CDR-H1 comprising SEQ ID NO: 14; a CDR-H2 comprising SEQ ID NO: 15; a CDR-H3 comprising SEQ ID NO: 16; a CDR-L1 comprising SEQ ID NO: 17; a CDR-L2 comprising SEQ ID NO: 18; and a CDR-L3 comprising SEQ ID NO: 19.
wherein a first source gas used in said forming the first boron-doped amorphous thin film includes boron-based gas and silane-based gas and be supplied to the seed layer, and a second source gas used in said forming the second boron-doped amorphous thin film includes the boron-based gas, the second source gas being different from the first source gas and being supplied to the first boron-doped amorphous thin film.
1. A seed of pea line SV6844QG, a sample of seed of said line having been deposited under ATCC Accession Number PTA-124090.
removing water and the organic solvent from the solution.
(ii) a second arm comprising (a) a heavy chain variable region CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 15; (b) a heavy chain variable region CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 31; (c) a heavy chain variable region CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 47; (d) a light chain variable region CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 62; (e) a light chain variable region CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 78; and (f) a light chain variable region CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 93.
1. A seed of pea line SV1231QF, a sample of seed of said line having been deposited under ATCC Accession Number PTA-124091.
1. A composition comprising: lycopene, astaxanthin and carnosic acid, wherein the molar concentration ratio of astaxanthin to carnosic acid is from 1:1 to 1:10.
1. An isolated nucleic acid encoding an anti-NSP4 antibody comprising a heavy chain and a light chain, wherein the light chain comprises an HVR-L1 comprising the sequence of SEQ ID NO:19, an HVR-L2 comprising the sequence of SEQ ID NO:11, and an HVR-L3 comprising the sequence of SEQ ID NO:12; and wherein the heavy chain comprisesan HVR-H1 comprising the sequence of SEQ ID NO:56, an HVR-H2 comprising the sequence of SEQ ID NO:57, and an HVR-H3 comprising the sequence of SEQ ID NO:58.
1. A pepper seed comprising at least a first set of the chromosomes of pepper line SBR-E712439 or pepper line SBR-E711416, a sample of seed of said lines having been deposited under ATCC Accession Number PTA-124022 and ATCC Accession Number PTA-124021, respectively.
1. A haircare product comprising an ostrich antibody against a hair loss-inducing substance as an antigen, wherein the hair loss-inducing substance is an enzyme or hormone which is the cause of alopecia, and wherein the hair loss-inducing substance comprises 5?-reductase, dihydrotestosterone, or 5?-reductase and dihydrotestosterone.
wherein the blending of the chemical compounds comprise 60.50% wt. of sodium chloride, 32.30% wt. of sodium lactate powder, 3.12% wt. of potassium chloride, 2.08% wt. of calcium chloride, and 2.00% wt. of xylitol.
(vi) said VL1 comprises the amino acid sequence of SEQ ID NO:4, said VH1 comprises the amino acid sequence of SEQ ID NO:3, said VL2 comprises the amino acid sequence of SEQ ID NO:91 and said VH2 comprises the amino acid sequence of SEQ ID NO:90.
wherein the non-racemic mixture comprises one or more salts of R-beta-hydroxybutyrate.
6) 2-aminothiazole;wherein the deposited electroless nickel layer has a measured gloss unit value above about 170.
wherein the non-racemic mixture comprises from 52% to 85% by enantiomeric equivalents of the S-beta-hydroxybutyrate and 48% to 15% by enantiomeric equivalents of the R-beta-hydroxybutyrate.
(4) adding 0.1 w/v % to 2.0 w/v % of the amino silane modified starch nanocrystal obtained from step (3) to a mixed solution of methanol and water containing 0.1 w/v % to 1.5 w/v % fluorescein isothiocyanate and keeping in dark place at room temperature for 12 to 36 h to obtain the fluorescent starch nanocrystal.
1. A pharmaceutical formulation comprising polymeric nanoparticles encapsulated within crosslinked polymeric microparticles, wherein the polymeric nanoparticles carry a therapeutic agent suitable for treatment of pulmonary arterial hypertension (PAH) loaded within them, wherein the therapeutic agent is selected from the group consisting of a prostacyclin synthetic analog, PPAR ? agonist, and NO donor, wherein the polymeric nanoparticles comprise a chitosan-derivative polymer selected from the group consisting of chitosan-PEG-Cholanic acid, chitosan-PEG-Stearic acid, and chitosan-PEG-Oleic acid, and wherein the PEG component of the polymer is connected to the chitosan component of the polymer by an ester bond, and wherein both the PEG component and the fatty acid component are connected to the same monosaccharide ring of the chitosan.
Step (2): purification: controlling the temperature at 20° C. to 30° C., adding the mixed reaction solution obtained in Step (1) into a dialysis bag, performing ultrasonic dialysis until the content of chloride ions is less than 10 ppm, decolorizing the dialysate by an absorbent active carbon, followed by filtrating to obtain a filtrate having ultraviolet absorption less than 0.5 AU, washing the active carbon twice by deionized water of 1 to 2 ml/g of the total input of the ?-cyclodextrin, combining wash solution with the filtrate, concentrating the combined wash solution and filtrate by a 0.65 to 0.22 ?m filter until the percentage of the sulfobutyl ether-?-cyclodextrin accounts for 30 wt % to 35 wt % of the total amount of the final solution, performing freeze-drying to obtain the sulfobutyl ether-?-cyclodextrin, and measuring an average 6.7 degree of substitution of the sulfobutyl ether group in capillary electrophoresis the amount of the ether solvent is 0.02 to 0.20 ml/g of the ?-cyclodextrin.
wherein the flame-retardant coating layer has a thickness of 5 to 10 ?m.
1. A method for preventing or reducing neurodegeneration in a human having the huntingtin gene mutation, comprising:administering to the human an effective amount of a composition comprising creatine hydrochloride, wherein the effective amount comprises a daily dose of creatine hydrochloride of about 2 grams to about 12 grams.
1.0?((VA)/(V0))?50 (2)wherein (V0) represents the inner volume [L] of the apparatus and (VA) represents the amount [L] of the solvent volatilizing per unit time [h].
1. A method of treating cancer in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of (3S)-3-amino-4-[5-[bis(2-chloroethyl)amino]-2-methyl-phenyl]butanoic acid (5), or a pharmaceutically acceptable salt thereof, wherein the cancer comprises glioblastoma, triple negative breast cancer, melanoma, prostate cancer, or multiple myeloma.
wherein the compressor lubricant comprises a mineral oil.
wherein the ethylene polymer has a melt index in a range from 0 to about 0.5 g/10 min, and a Mw in a range from about 400,000 to about 900,000 g/mol.
wherein less corrosion occurs to at least one metal surface as compared to an otherwise identical method without the contact of at least one metal surface with the apatite forming components.
1. A method of improving the visual processing of a healthy infant, the method comprising administering a nutritional composition comprising RRR-alpha-tocopherol to the infant.
R1k(C6H4-k)(COOR2)(COOR3) (1) andan organic compound represented the following general formula (2)R4R5C?C(COOR6)(COOR7) (2)into contact with each other at the same step,wherein R1 is a halogen atom or an alkyl group having 1 to 8 carbon atoms, R2 and R3 are a linear alkyl group having 1 to 6 carbon atoms, provided that R2 and R3 are either identical or different, and k is an integer from 0 to 4, provided that a plurality of R1 are either identical or different when k is an integer from 2 to 4, andwherein R4 and R5 are independently an atom or group selected from a hydrogen atom, halogen, a linear alkyl group having 1 to 20 carbon atoms, a branched alkyl group having 3 to 20 carbon atoms, a vinyl group, a linear or branched alkenyl group having 3 to 20 atoms, a cycloalkenyl group having 3 to 20 carbon atoms, an aromatic hydrocarbon group having 6 to 20 carbon atoms, provided that R4 and R5 optionally bond to each other to form a ring, and the number of carbon atoms of R5 is 2 or more when R4 is a hydrogen atom or a methyl group; andwherein R6 and R7 are independently a linear alkyl group having 1 to 20 carbon atoms, a branched alkyl group having 3 to 20 carbon atoms, a vinyl group, a linear or branched alkenyl group having 3 to 20 carbon atoms, a cycloalkyl group having 3 to 20 carbon atoms, a cycloalkenyl group having 3 to 20 carbon atoms, or an aromatic hydrocarbon group having 6 to 20 atoms.
(c) generating a pig from said cell whose genome comprises either a heterozygous or homozygous modification of the RELA gene, wherein said pig expresses a truncated RelA protein that lacks transactivation domain 1 and exhibits a phenotype of reduced NFkappaB signaling capacity when compared to a wild type pig.
7. A process according to claim 6, wherein the preform comprises one or more layers of fabric comprising reinforcing fibrous material.
an anode in contact with the electrolyte solution, wherein the anode comprises a material selected from the group consisting of vitreous carbon, reticulated vitreous carbon, woven carbon fibers, and combinations of one or more of the foregoing.
1. A pharmaceutical combination comprising a first active ingredient which is (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one or a pharmaceutically acceptable salt thereof and a second active ingredient which is dimethyl fumarate.
converting the polymeric particle to the hydrogel particle, wherein converting the polymeric particle includes removing at least a portion of the plurality of the hydrophobic protection groups from the polymeric particle.
wherein the membrane is at least one layer of a battery separator.
wherein the article is at least one of one or more electrically conductive wires in an overhead conductor.
and wherein applying the formulation results in a mean plasma Cmax in a population of at least 15 adult onychomycosis patients after 28 days of once daily treatment that is less than 0.8 ng/mL.
a mass ratio of the ethylene-vinyl alcohol copolymer (A) to the block copolymer (B) is 52/48 or greater and 63/37 or less.
component (D): an ?-hydroxy acetophenone-based radical initiator having thermal decomposition temperature of 200° C. or higher.
when the insulating particle paint is applied onto the electrode active material layer in the wet state, a contact angle of the insulating particle paint on the electrode active material layer in the wet state is in a range of 10 to 40°.
an oil gelling agent,wherein the one or more volatile substances are comprised in an amount of from 70.0 to 99.0% by weight by the insect pest-targeting gel composition,wherein the oil gelling agent is selected from the group consisting of a long-chain fatty acid, a dextrin fatty acid ester, a sucrose fatty acid ester, a fructooligosaccharide fatty acid ester, a benzylidene derivative of sorbitol, and wax, andwherein the oil gelling agent is not a polyvalent metal salt of a long-chain fatty acid or 12-hydroxystearic acid.
1. An acoustic-wave probe, comprising at least one selected from the group consisting of an acoustic lens and an acoustic matching layer, which comprise a silicone resin for an acoustic-wave probe, in which a composition for an acoustic-wave probe is hardened,the composition for an acoustic-wave probe comprising a polysiloxane mixture, and wherein the polysiloxane mixture comprises: a polysiloxane having a vinyl group; a polysiloxane having at least two SiH groups in the molecular chain thereof; and silica particles having an average primary particle size of less than 12 nm.
wherein the comb-length of the comb-block polyolefin is greater than the entanglement molecular weight of atactic polypropylene.
wherein said reaction vessel and/or reaction manifold is in fluid connection with said outlet to dispense said peroxycarboxylic acid composition.
units of at least one hydrophilic vinylic monomer,wherein the silicone hydrogel contact lens, when being fully hydrated, has an oxygen permeability (Dk) of at least about 70 barrers, a water content of from about 25% to about 70% by weight, and an elastic modulus of from about 0.2 MPa to about 1.2 MPa.
wherein the amount of the alkaline compound is from about 0.073 wt % to about 0.13 wt % to the total weight of the scouring solution.
1. A herbicidal composition comprising saflufenacil and 2,4-D choline salt, wherein the weight ratio of saflufenacil to 2,4-D choline salt is from 1:0.5 to 1:100.
9. A method of controlling phytopathogenic fungi comprising treating a seed or a plant with a fungicide and a safener, wherein the safener is mefenpyr diethyl and wherein the fungicide is tebuconazole, wherein the mefenpyr diethyl and the tebuconazole are applied to the seed or plant in synergistic amounts, wherein the weight ratio of mefenpyr diethyl to tebuconazole is from 50:1 to 1:50.
1. A method of treating an ACVR1-mediated disease comprising administering momelotinib or a pharmaceutically acceptable salt or solvate thereof to a patient in need thereof, wherein the ACVR1-mediated disease is selected from the group consisting of fibrodysplasia ossificans progressive (FOP) and diffuse intrapontine glioma (DIPG).
1. A method of inhibiting the histone methyltransferase activity of EZH2 in a subject in need thereof comprising administering to the subject an effective amount of a solid crystalline form of N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide, wherein the solid crystalline form exhibits an X-ray powder diffraction pattern having one or more characteristic peaks expressed in degrees 2-theta at about 3.9+/?0.3 degrees, about 17.5+/?0.3 degrees, and about 22.0+/?0.3 degrees 2-theta.
1. A composition comprising a semisolid epoxy resin containing a curative dispersed therein, said curative having a particle size such that at least 90% of the particles have a size below 25 ?m at ambient temperature of 21° C., as determined in accordance with ASTM D1214, wherein the composition further comprises a diluent; said diluent comprising a particulate filler selected from micro balloons, glass, carbon, metal and/or combinations of the aforesaid fillers;and wherein, said composition further comprises a fibrous material, comprising a fleece.
wherein the antiseptic composition prevents sporulation of vegetative cells.
wherein said at least one FR cellulosic fiber and said at least one untreated cellulosic fiber are assembled together as a fiber barrier nonwoven material.
wherein the degree of swelling is measured using an electrolyte solution obtained by dissolving LiPF6 with a concentration of 1.0 M in a mixed solvent of ethylene carbonate and ethyl methyl carbonate with a volume ratio of 3/7 and vinylene carbonate with a solvent ratio of 2 mass %.
1. A method of promoting root growth of a plant, the method comprising contacting the plant, or a seed of the plant, with a composition comprising forchlorfenuron (CPPU) before the reproductive growth stage of the plant, such that either the root length of the plant is at least 5% greater than for an untreated plant, or the ratio of root length to stem length is increased by at least 5% compared to the untreated plant, wherein the plant is a member of the genus Gossypium, wherein the concentration of CPPU in the composition is from about 2 to about 50 ppm when the plant is contacted, and wherein the concentration of CPPU in the composition, is from about 25 to about 1000 ppm in the composition when the seed is contacted.
2) an active agent selected from the group consisting of diazepam, oxazepam, lorazepam, clonazepam, bromazepam, alprazolam, clotiazepam, clobazam, buspirone, amphetamine, methamphetamine, methylphenidate, cathine, fenfluramine, piracetam, and meclofenoxate, in an amount of 10% or less;wherein said thermotropic liquid crystal transmembrane penetration enhancer delivers said active agent through the skin of the patient when said cholesteryl esters are in a mesomorphic state.
1. A method of enhancing growth of a plant comprising the steps of: (a) spraying a composition of matter on the stems or leaves of a plant, wherein said composition comprises water and an effective concentration of carbon nanomaterials in the range of 0.1-200 ?g/mL, wherein said carbon nanomaterials comprises single-walled nanotubes, multi-walled nanotubes, nanofibers, or fullerenes; and (b) selecting a plant having an increased number of flowers as compared to a non-treated plant.
iii. 10-15 percent by weight of a mixture of borage oil and peppermint oil.
wherein the hydrogen peroxide producing compound is present in the composition in an amount greater than or equal to about 85% by weight and the chelating agent is present in the composition in an amount of from about 0.1% to about 1.5% by weight.
1. A method of treating an otorhinolaryngology-associated pathology, or Head and Neck associated pathology in a subject, comprising administering through the auditory bulla a composition onto the round window membrane of the subject for release of an agent to the perilymph of the inner ear of the subject, wherein said composition comprises a solution of chitosan-glycerophosphate (CGP) and the agent, wherein the agent dissolved therein is present in an amount effective in the treatment of the otorhinolaryngology-associated pathology, or Head and Neck associated pathology, wherein auditory functions are preserved by said administering.
wherein the water contact angle is between 20° and 25°.
exposing the titanium dioxide-containing Myrtus communis plant to contaminant-containing air comprising at least one contaminant selected from the group consisting of CO2, SO2, formaldehyde, CO, benzene, toluene, xylene, and ethyl benzene, wherein a contaminant concentration in the contaminant-containing air is reduced by 10% to 98% relative to a contaminant concentration in the contaminant-containing air prior to the exposing.
1. A co-crystal comprising (rac)-tramadol.HCl and celecoxib in a molecular ratio of 1:1, characterized in that it has an orthorhombic unit cell with the following dimensions:a=11.0323(7) ?
1. A method for inhibiting or reducing fungal growth in grain, comprising exposing the grain to a composition comprising one or more bacteria, wherein the one or more bacteria are selected from the group consisting of Rhodococcus rhodochrous DAP 96253, Rhodococcus rhodochrous DAP 96622, Rhodococcus erythropolis, and combinations thereof, and wherein the one or more bacteria are provided in a quantity sufficient to inhibit or reduce fungal growth on the grain.
1. A method of treating hepatic steatosis in a patient comprising orally administering an effective amount of an ileal brake composition in an oral dosage form comprising an ileal brake compound wherein at least 50% by weight of the ileal brake compound administered to said patient is released in the ileum of the patient.
wherein the thermoplastic polymer comprising the fibres embedded therein is provided in layerwise fashion, in that the layers are compressed to afford a stack in the absence of the main body/the semifinished precursor thereof and in that the sequence of steps f) and q) is effected by placing and pressing the stack onto the main body/the semifinished precursor thereof.
from 0.1% to 12% by weight of an alcohol or of an alcoholate, relative to the total weight of the composition.
wherein the one or more further structures comprise columns having a height in a range from about 0.01 microns to about 500 microns and being spaced apart in a range from about 0.1 microns to about 500 microns.
without the addition of organic solvent(s) which at 0.1 MPa and 20° C. are soluble to a maximum extent of 1% by weight in water.
wherein said composition is administered in an amount sufficient to reduce the number of ulcers in the subject by the fifth day of said single episode.